Neurological disorders constitute a major health and socioeconomic problem. They represent the second cause of death and the leading cause of disability throughout the world. Despite the implementation of strategies and intervention programs to reduce the burden, over the past 25 years, the incidence, prevalence, mortality, and disability rates of neurological disorders are rising globally, mainly due to population aging and growth (1) . This has placed heavy pressure on health-care systems pointing out the urgent need to identify new strategies to improve patient outcomes and reduce health costs by enabling more effective drug development and establishing a more personalized medicine approach.
Rapid scientific and technical advances have enabled reliable and affordable measurement of novel biomarkers-biological indicators that objectively measure and evaluate physiological or pathophysiological processes or pharmacological responses to a therapeutic intervention (2)-which have been suggested to help assessment and management of patients with neurological disorders beyond current practice standards (3) (4) (5) . Evidence suggests a potential variety of clinical applications, including enhancing diagnostic and prognostic accuracy, improving the existing decision criteria for early diagnosis and risk stratification, as well as assisting in disease monitoring, and acting as surrogate endpoints in experimental studies and clinical trials (6) (7) (8) (9) (10) . In addition, biomarkers may reliably capture the different aspects of disease heterogeneity and pathogenesis, helping characterize patients, and thereby informing targeted tailored treatments and predicting response outcomes to interventions (11) (12) (13) (14) (15) (16) (17) (18) . However, despite large numbers of candidate biomarkers have been proposed and extensively evaluated, very few are currently integrated into routine clinical practice and the quest for novel brain injury markers in still ongoing (19) .
This book aimed at providing an overview of the biomarker landscape in neurological disorders. The diverse authors discuss established and emerging biomarkers as well as innovative strategies for identifying novel candidates offering new and unique perspectives. Several articles in this volume have been focused on Alzheimer's disease and other neurodegenerative disorders, exploring potentially relevant genetic signature (Chen et al.) and the pathogenetic and prognostic role of circulating cytokines (Kim et al.). Importantly, using a methodologically novel approach that combines computational prediction and experimental validation, Yao et al., for the first time, identified VLDLR, an apolipoprotein E receptor involved in synaptic plasticity, as a circulating signature for Alzheimer's disease. Accordingly, several lines of evidence are pointing toward the added and complementary value of markers of synaptic function owing to their close link with cognitive deterioration (20) .
Contemporary investigations on microRNAs (miRNAs) (Di Pietro et al.) and high mobility group box protein 1 (HMGB1) (Paudel et al.) are also presented, highlighting the fact that these markers may be risk factors themselves and therefore potential targets of therapy (21) 
ACKNOWLEDGMENTS
We thank our colleagues for devoting their time, expertise and effort in producing valuable contributions that provide rigorous frameworks and innovative and critical insights. This book would not have been possible without their important work. It is also a pleasure to acknowledge and thank the editorial team for their expert assistance and support in the development and production of this volume. Finally, with our utmost gratitude and profound respect, we want to dedicate this book to all patients and their families. We are indebted to their sacrifices and unfailing spirit of hope which represent our greatest source of inspiration.
